N/A N=28 Participation and Environment Measure-Plus (PEM-Plus) Care Planning Intervention
Developmental Disability · Early Intervention (Education)
Primary: Mean Retention Rates — 18 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=92 Acupuncture for PTSD
Posttraumatic Stress Disorder
Primary: Change in PTSD Symptom Severity on the Clinician Administered PSTD Scale - CAPS 5 From Before to After Treatment — 22.6; 29.1 score on a scale
N/A N=73 Total Knee Replacement With Tourniquet or Aquamantys
Knee Replacement
Primary: Isometric Quadriceps Strength — 11.58; 9.60 Nm/kg
N/A N=74 Caregiver Self-Management Needs Through Skill-Building
Family Caregivers · Stroke
Primary: Caregiver Satisfaction Ratings for Both TASK III and ISR Programs Measured by the Caregiver Satisfaction Scale (CSS). — 4.59; 4.15 score on a scale
Phase 3 N=159 An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
Eosinophilic Gastritis · Eosinophilic Duodenitis
Primary: The Safety and Tolerability of Lirentelimab by Evaluating Adverse Events Assessed Using the CTCAE Version 5.0 — 66; 75; 33; 29 Participants
Phase 3 N=332 A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis
Osteoporosis, Postmenopausal
Primary: Percent Change From Baseline in LS-BMD at Week 52 — 4.76; 4.54 percentage of change from baseline
N/A N=95 Adapting Diet and Action for Everyone (ADAPT+)
Pediatric Obesity
Primary: Acceptability — 3.91; 3.85 score on a scale
Phase 3 N=245 Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old
Diabetes Mellitus, Type 2
Primary: Dapagliflozin Versus Placebo: Adjusted Mean Change From Baseline in HbA1c at Week 26 — -0.62; 0.41 Percentage HbA1c — p=< 0.001
N/A N=182 Active for Life: Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Primary: Time Spent in Physical Activity as Measured by Upright Time (Minutes Per Day) Monitored by ActivPal Monitor — 278; 269; 293; 285 minutes per day
Phase 1 N=26 Behavioral Pharmacology of Cannabis and Nicotine
Cannabis · Nicotine
Primary: Amount of Nicotine (mL of Smoke/Vapor) Inhaled — 0; 489.0; 1814.0; 1401.0 Volume in mL
N/A N=34 Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)
Type 1 Diabetes
Primary: Number of Severe Hypoglycemic Events — 0 events
N/A N=536 ART First-line Treatment Durability in Russia
HIV-1-infection
Primary: 48 Weeks Treatment Durability — 76.0 percentage of participants
N/A N=39 Preliminary Study 2 to Test the Effects of Ambulatory Voice Biofeedback
Vocal Fold Nodules · Muscle Tension Dysphonia
Primary: Percent Compliance — 89.04; 92.44; 90.76 percentage of voicing crossing threshold
N/A N=155 Improving Outcomes Among Medical/Surgical Inpatients With Alcohol Use Disorders
Alcohol Use Disorder
Primary: Time Line Follow Back — 48; 56 percentage of participants abstinent — p=<.05
Phase 2 N=226 Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension
Open-Angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure Over 84 Days — 22.0; 22.5; 18.8; 19.4 mmHg